Hoeflich and colleagues [43] found that basal cell breast cancers expressed a Ras-like expression profile and tested their hypothesis that these breast cancers could be sensitive to MEK inhibitors, providing that they do not have PI3KCA mutations or PTEN deletions. The gene discussed is PTEN; the disease is breast carcinoma.